Structure-activity relationships of tariquidar analogs as multidrug resistance modulators

AAPS Journal

Volumn 11, Issue 3, 2009, Pages 435-444

  Pajeva, Ilza K ^a   Wiese, Michael ^b  

^a CENTRE OF BIOMEDICAL ENGINEERING   (Bulgaria)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

BCRP; Modeling; Multidrug resistance; P glycoprotein; Pharmacophore; QSAR

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; HOE 33342; TARIQUIDAR; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; XR 9456; XR 9504; XR 9544; XR 9577;

DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HYDROPHOBICITY; IC 50; MULTIDRUG RESISTANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

DRUG RESISTANCE, MULTIPLE; MODELS, MOLECULAR; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73349111250     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9118-z     Document Type: Review

References (52)

1. I Klein B Sarkadi A Varadi 1999 An inventory of the human ABC proteins Biochim Biophys Acta. 1461 237 262 10581359 10.1016/S0005-2736(99)00161-3 1:CAS:528:DyaK1MXns1agtLs%3D
2. T Fojo S Bates 2003 Strategies for reversing drug resistance Oncogene. 22 7512 7523 14576855 10.1038/sj.onc.1206951 1:CAS:528:DC%2BD3sXotlaju7g%3D (Pubitemid 37487173)
3. A Bodo E Bakos F Szeri A Varadi B Sarkadi 2003 The role of multidrug transporters in drug availability, metabolism and toxicity Toxicol Lett. 140 133 143 12676459 10.1016/S0378-4274(02)00497-6 (Pubitemid 36378931)
4. RL Juliano V Ling 1976 A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim Biophys Acta. 455 152 162 990323 10.1016/0005-2736(76)90160-7 1:CAS:528:DyaE28XlvV2qs70%3D
5. MM Gottesmann I Pastan 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter Annu Rev Biochem. 62 385 427 10.1146/annurev.bi. 62.070193.002125
6. SV Ambudkar S Dey CA Hrycyna M Ramachandra I Pastan MM Gottesman 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol. 39 361 398 10331089 10.1146/annurev.pharmtox.39.1. 361 1:CAS:528:DyaK1MXjtVejtLo%3D (Pubitemid 29222564)
7. SEL Mirski JH Gerlach SPC Cole 1987 Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin Cancer Res. 47 2594 2598 2436751 1:CAS:528:DyaL2sXkslSgtL4%3D
8. A Boumendjel H Baubichon-Cortay D Trompier T Perrotton A Di Pietro 2005 Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents Med Res Rev. 25 453 472 15834856 10.1002/med.20032 1:CAS:528:DC%2BD2MXntlSkur8%3D (Pubitemid 40946536)
9. DR Hipfner RG Deeley SPC Cole 1999 Structural, mechanistic and clinical aspects of MRP1 Biochim Biophys Acta. 1461 359 376 10581367 10.1016/S0005- 2736(99)00168-6 1:CAS:528:DyaK1MXns1agtb0%3D
10. EM Leslie RG Deeley SPC Cole 2001 Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters Toxicology. 167 3 23 11557126 10.1016/S0300-483X(01)00454-1 1:CAS:528: DC%2BD3MXms12nurk%3D (Pubitemid 32830943)
11. H Kusuhara Y Sugiyama 2007 ATP-binding cassette, subfamily G (ABCG family) Pflugers Arch. 453 735 744 16983557 10.1007/s00424-006-0134-x 1:CAS:528:DC%2BD2sXhtFWjt7g%3D (Pubitemid 46192543)
12. LA Doyle WD Yang LV Abruzzo, et al. 1998 A multidrug resistance transporter from human MCF-7 breast cancer cells Proc Natl Acad Sci U S A. 95 15665 15670 9861027 10.1073/pnas.95.26.15665 1:CAS:528:DyaK1MXhvFeitQ%3D%3D (Pubitemid 29018757)
13. T Litman M Brangi E Hudson, et al. 2000 The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J Cell Sci. 113 2011 2021 10806112 1:CAS:528:DC%2BD3cXksVKntrg%3D
14. RW Robey O Polgar J Deeken KW To SE Bates 2007 ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev. 26 39 57 17323127 10.1007/s10555-007-9042-6 1:CAS:528:DC%2BD2sXjt1KqtL0%3D (Pubitemid 46452182)
15. M Maliepaard MA van Gastelen A Tohgo, et al. 2001 Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918 Clin Cancer Res. 7 935 941 11309344 1:CAS:528:DC%2BD3MXjs1elsbo%3D
16. BL Abbott 2006 ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells Clin Adv Hematol Oncol. 4 63 72 16562373
17. T Tsuruo H Iida S Tsukagoshi Y Sakurai 1982 Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin Biochem Pharmacol. 31 3138 3140 7150340 10.1016/0006-2952(82)90097-1 1:CAS:528:DyaL38XmtVOqsrw%3D
18. H Thomas HM Coley 2003 Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein Cancer Control. 10 159 165 12712010
19. J Robert C Jarry 2003 Multidrug resistance reversal agents J Med Chem. 46 4805 4817 14584929 10.1021/jm030183a 1:CAS:528:DC%2BD3sXnvFOisb8%3D
20. R Krishna LD Mayer 2000 Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci 11 265 283 11033070 10.1016/S0928-0987(00)00114-7 1:CAS:528:DC%2BD3cXntF2gtLw%3D (Pubitemid 30738405)
21. Ryder, H, Ashworth PA, Roe MJ, et al. Anthranilic acid derivatives as multi drug resistance modulators. WO98/17648, April 30, 1998.
22. M Roe A Folkes P Ashworth, et al. 1999 Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives Bioorg Med Chem Lett. 9 595 600 10098671 10.1016/S0960-894X(99)00030-X 1:CAS:528: DyaK1MXhvVylsrs%3D (Pubitemid 29090660)
23. Klinkhammer W. Design, Synthese und 3D-QSAR neuartiger P-gp-Modulatoren. [Ph D thesis]. Bonn: University of Bonn; 2006. URN: urn:nbn:de:hbz:5 N-08459. http://deposit.ddb.de/cgi-bin/dokserv?idn=981124488&dok-var=d1&dok-ext= pdf&filename=981124488.pdf.
24. V Jekerle W Klinkhammer RM Reilly M Piquette-Miller M Wiese 2007 Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties Cancer Chemother Pharmacol. 59 61 69 16636798 10.1007/s00280-006-0244-3 1:CAS:528:DC%2BD28Xht1entL%2FJ (Pubitemid 44796103)
25. V Jekerle W Klinkhammer DA Scollard K Breitbach RM Reilly M Piquette-Miller M Wiese 2006 In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques Int J Cancer 119 414 422 16646006 10.1002/ijc.21827 1:CAS:528:DC%2BD28XmsVOjtb0%3D (Pubitemid 43911908)
26. H Müller W Klinkhammer C Globisch MU Kassack IK Pajeva M Wiese 2007 New functional assay of P-glycoprotein activity using Hoechst 33342 Bioorg Med Chem. 15 7470 7479 17890094 10.1016/j.bmc.2007.07.024 (Pubitemid 47539132)
27. H Müller IK Pajeva C Globisch M Wiese 2008 Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors Bioorg Med Chem. 16 2448 2462 18083034 10.1016/j.bmc.2007.11.057
28. W Klinkhammer H Müller C Globisch IK Pajeva M Wiese 2009 Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators Bioorg Med Chem. 17 2524 2535 19250834 10.1016/j.bmc.2009.01.072 1:CAS:528:DC%2BD1MXjsFWqu7Y%3D
29. P Labrie SP Maddaford J Lacroix, et al. 2006 In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450 Bioorg Med Chem. 14 7972 7987 16904325 10.1016/j.bmc.2006.07.055 1:CAS:528:DC%2BD28XhtFSrtLbI (Pubitemid 44596258)
30. P Labrie SP Maddaford J Lacroix, et al. 2007 In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2) Bioorg Med Chem. 15 3854 3868 17399990 10.1016/j.bmc.2007.03.014 1:CAS:528:DC%2BD2sXkslCitb4%3D (Pubitemid 46661801)
31. Egger M, Li X, Müller C, Bernhardt G, Buschauer A, König B. Tariquidar analogues: synthesis by CuI-catalysed N/O-aryl coupling and inhibitory activity against the ABCB1 transporter. Eur J Org Chem. 2007;2643-49.
32. M Kühnle M Egger C Müller, et al. 2009 Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-glycoprotein (ABCB1) modulator tariquidar J Med Chem. 52 1190 1197 19170519 10.1021/jm8013822
33. P Mistry AJ Stewart W Dangerfield, et al. 2001 In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res 61 749 758 11212278 1:CAS:528:DC%2BD3MXht1Gmt78%3D
34. J Walker C Martin R Callaghan 2004 Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy Eur J Cancer. 40 594 605 14962729 10.1016/j.ejca.2003.09.036 1:CAS:528: DC%2BD2cXhtFWjtrw%3D (Pubitemid 38220779)
35. S Kohler WD Stein 2003 Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles Biotechnol Bioeng. 81 507 517 12514799 10.1002/bit.10488 1:CAS:528:DC%2BD3sXhtFKis7c%3D (Pubitemid 36222309)
36. Leyers S, Wiese M. Tariquidar at a concentration of 10 μM has no effect on MRP1 activity in 2008MRP1 cells. Unpublished results.
37. RW Robey K Steadman O Polgar, et al. 2004 Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res. 64 1242 1246 14973080 10.1158/0008-5472.CAN-03-3298 1:CAS:528:DC%2BD2cXhtleisb4%3D (Pubitemid 38235589)
38. E Fox SE Bates 2007 Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor Expert Rev Anticancer Ther. 7 447 459 17428165 10.1586/14737140.7.4.447 1:CAS:528:DC%2BD2sXkt1Wqs70%3D (Pubitemid 46681800)
39. C Globisch IK Pajeva M Wiese 2006 Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators Bioorg Med Chem. 14 1588 1598 16307883 10.1016/j.bmc.2005.10.058 1:CAS:528: DC%2BD28XmsVGhtA%3D%3D (Pubitemid 43120295)
40. A Pick H Müller M Wiese 2008 Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2) Bioorg Med Chem. 16 8224 8236 18678495 10.1016/j.bmc.2008.07.034 1:CAS:528:DC%2BD1cXhtVyktbbF
41. C Martin G Berridge P Mistry C Higgins P Charlton R Callaghan 1999 The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein Br J Pharmacol. 128 403 411 10510451 10.1038/sj.bjp.0702807 1:CAS:528:DyaK1MXmsFWgs70%3D (Pubitemid 29458600)
42. C Martin G Berridge CF Higgins P Mistry P Charlton R Callaghan 2000 Communication between multiple drug binding sites on P-glycoprotein Mol Pharmacol. 58 624 632 10953057 1:CAS:528:DC%2BD3cXmtFCqtbo%3D
43. B Shapiro V Ling 1997 Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities Eur J Biochem. 250 130 137 9432000 10.1111/j.1432-1033.1997.00130.x 1:CAS:528:DyaK2sXnslGgt7o%3D
44. AB Shapiro K Fox P Lam V Ling 1999 Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site Eur J Biochem. 259 841 850 10092872 10.1046/j.1432-1327.1999.00098.x 1:CAS:528:DyaK1MXhsFejsbg%3D (Pubitemid 29075514)
45. Q Qu F Sharom 2002 Proximity of bound hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmatic membrane leaflet Biochemistry 41 4744 4752 11926837 10.1021/bi0120897 1:CAS:528:DC%2BD38XhslOgs7s%3D (Pubitemid 34275675)
46. T Litman T Skovsgaard WDJ Stein 2003 Pumping of drugs by P-glycoprotein: a two-step process? Pharmacol Exp Ther. 307 846 853 10.1124/jpet.103.056960 1:CAS:528:DC%2BD3sXpslShs7w%3D (Pubitemid 37494200)
47. RV Kondratov PG Komarov Y Becker A Ewenson AV Gudkov 2001 Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein Proc Natl Acad Sci U S A. 98 14078 14083 11707575 10.1073/pnas.241314798 1:CAS:528:DC%2BD3MXovVymsrs%3D (Pubitemid 33116027)
48. IK Pajeva C Globisch M Wiese 2004 Structure-function relationships of multidrug resistance P-glycoprotein J Med Chem. 47 2523 2533 15115395 10.1021/jm031009p 1:CAS:528:DC%2BD2cXjtVSqsrY%3D (Pubitemid 38580090)
49. P Labrie SP Maddaford S Fortin, et al. 2006 A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators J Med Chem. 49 7646 7660 17181148 10.1021/jm060239b 1:CAS:528:DC%2BD28Xht1yrtrnJ (Pubitemid 46033657)
50. Müller, H. Funktionelle Untersuchungen des ABC-transporters P-glykoprotein. PhD thesis, University of Bonn, Bonn; 2007. urn:nbn:de:hbz:5N- 12814. http://hss.ulb.uni-bonn.de/diss-online/math-nat-fak/2007/mueller-henrik.
51. I Pajeva C Globisch R Fleischer I Tsakovska M Wiese 2005 Molecular modeling of P-glycoprotein and related drugs Med Chem Res. 14 106 117 10.1007/s00044-005-0127-x 1:CAS:528:DC%2BD2MXhtlegtrnI (Pubitemid 43187053)
52. IK Pajeva M Wiese 1998 Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study J Med Chem. 41 1815 1826 9599232 10.1021/jm970786k 1:CAS:528: DyaK1cXis12qu7k%3D (Pubitemid 28248657)